Group to explore potential of innovation that integrates MRI technology and radiation therapy delivery
STOCKHOLM and MILWAUKEE, July 16 – Elekta (NSE: EKTAb) and Royal Philips (NYSE: PHG, AEX: PHIA) announced today that the Froedtert & The Medical College of Wisconsin Clinical Cancer Center (Milwaukee, Wisconsin) will join a consortium that is investigating the development of a magnetic resonance imaging (MRI) guided radiation therapy system.
“The Froedtert & Medical College of Wisconsin Clinical Cancer Center is an exceptional addition to the consortium,” says Tomas Puusepp, Elekta President and CEO. “It is a nationally renowned cancer research institute, boasts in-depth expertise in every kind of cancer, is staffed by fully coordinated specialist teams and uses the latest innovative therapies and technologies.”
The Froedtert & Medical College of Wisconsin Clinical Cancer Center is the fifth member to sign the research agreement to evaluate the new technology, which unites radiation therapy and MRI in a single system. Current clinical members of the group include the University Medical Center Utrecht (Utrecht, the Netherlands), The University of Texas MD Anderson Cancer Center (Houston, Texas), The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (Amsterdam, the Netherlands) and Sunnybrook Health Sciences Centre (Toronto, Ontario).
Integrating an advanced 1.5 Tesla MRI machine with a sophisticated adaptive radiation therapy system will provide physicians with depictions of a patient’s soft tissues and tumor and allow them to dynamically track their motion. This innovation is designed to enable clinicians to deliver radiation under real-time MR guidance.
“We are eager to join this consortium of leading institutions. The research and clinical faculty of our cancer center will bring a wealth of expertise and experience to the exploration of MR-guided radiation therapy,” says J. Frank Wilson, MD, Chairman, Director Emeritus of the Froedtert & Medical College of Wisconsin Clinical Cancer Center. The delivery system of the future will be adaptive, enabling real-time changes to radiation treatments that respond to changing anatomy, tumor response and potentially to changes in tumor biology that occur during treatment.”
“Combining adaptive radiation therapy with real-time MR imaging is a powerful new concept that has the potential to redefine the standard of care in radiation oncology,” says Gene Saragnese, CEO Imaging Systems at Philips Healthcare. “Partnering with clinical centers of excellence like the Froedtert & The Medical College of Wisconsin Clinical Cancer Center will enable us to explore the clinical applications of this new technology and ultimately create the future of healthcare.”
The integrated MRI-guided radiation therapy system is in development and not available for sale.
# # #
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on July 16, 2013.
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com.
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447
Time zone: ET: Eastern Time
Steve Klink, Philips Corporate Communications
Tel: +31 6 10888824
Time zone: CET: Central European Time